Adjuvant development in the context of seasonal and pandemic influenza

季节性和大流行性流感背景下的佐剂开发

• 批准号: 10455393
• 负责人: JAY EVANS
• 金额: $ 358.38万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10455393
• 关键词: Adjuvant; Development; Disease; Human; Immunologics; Influenza; Influenza A Virus, H7N9 Subtype; Influenza B Virus; Investigation; Licensure; Ligands; Support Contracts; System; TLR4 gene; TLR7 gene; Testing; Vaccines; human disease; nanoparticle; pandemic disease; pandemic influenza; pathogen; seasonal influenza

This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.

该合同支持通过免疫学表征研究和化合物优化开发佐剂，包括IND使能研究。主要重点将是测试和进一步开发用于人类许可的佐剂，作为许可或研究疫苗的组成部分，以防止一种或多种与人类疾病相关的非HIV疾病病原体。